Information  X 
Enter a valid email address

Medgenics Inc (MEDG)


Tuesday 09 July, 2013

Medgenics Inc

Block Listing Interim Review

RNS Number : 8935I
Medgenics Inc
09 July 2013




Press Release

9 July 2013


Medgenics, Inc.

(the "Company")


Block Listing Interim Review



1. Name of company:


Medgenics, Inc.


2. Name of scheme:


Warrants, Options and Restricted Shares under the Company's Share Incentive Schemes


3. Period of return:            




6 January 2013

5 July 2013



4. Number and class of securities not issued under the scheme at the beginning of the period:


(i)         MEDG TIDM - 725,315 common shares of par value of US$0.0001 each ("Common Shares") Regulation S restrictions, ISIN USU582411158 ("Reg S"); and


(ii)        MEDU TIDM - 549,081 Common Shares ISIN US58436Q2030



5. Number of securities issued under scheme during period:


(i)         MEDG TIDM (Reg. S) - 10,000 Common Shares following Restricted Shares issued by the Company


(ii)        MEDU TIDM - 3,500 Common Shares following the due exercise of options issued by the Company



6. Balance under scheme of securities not yet issued at end of period:


(i)         MEDG TIDM (Reg. S) - 715,315 Common Shares


(ii)        MEDU TIDM - 545,581 Common Shares



7. Number and class of securities originally admitted and the date of admission:


(i)         MEDG TIDM (Reg. S) - 963,119 Common Shares (6 July 2011)


(ii)        MEDU TIDM - 963,119 Common Shares (6 July 2011).


Following the above issues during the period the total number of Common Shares in issue is 18,481,308. The percentage of shares not in public hands is 17.8 per cent.



For further information, contact:

Medgenics, Inc.

Dr. Andrew L. Pearlman

[email protected]

Phone: +972 4 902 8900


Abchurch Communications

Joanne Shears

Jamie Hooper

Harriet Rae

[email protected]


Phone: +44 207 398 7718

SVS Securities plc (Joint Broker)

Alex Brearley


Phone: +44 207 638 5600


Nomura Code Securities (NOMAD/Broker)

Jonathan Senior

Giles Balleny


Phone: +44 207 776 1219




About Medgenics


Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis and hemophilia, among others. For more information, please visit   


Forward-looking Statements


This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.




- ENDS -


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t